Pharmicell KRX:005690KOSPI
파미셀 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Pharmicell reported revenue of ₩39.0bn, up 45.7% year on year, and operating profit of ₩13.2bn. Pharmicell (파미셀) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Pharmicell quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩39.0bn | +45.7% | ₩13.2bn | ₩10.4bn |
| Q1 2026 | ₩36.7bn | +35.7% | ₩13.1bn | ₩11.7bn |
| Q4 2025 derived | ₩34.6bn | +61.2% | ₩9.6bn | ₩15.7bn |
| Q3 2025 | ₩25.6bn | +75.7% | ₩8.1bn | ₩8.8bn |
| Q2 2025 | ₩26.8bn | +50.3% | ₩8.2bn | ₩7.4bn |
| Q1 2025 | ₩27.0bn | +146.3% | ₩8.4bn | ₩8.5bn |
| Q4 2024 derived | ₩21.5bn | +62.5% | ₩3.1bn | ₩4.2bn |
| Q3 2024 | ₩14.6bn | +19.9% | ₩1.3bn | ₩714m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Pharmicell top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Pharmicell news Korean headlines
No articles yet.